-
1
-
-
61349099439
-
Diagnosis and classification of diabetes mellitus
-
American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl. 1):62–67
-
(2009)
Diabetes Care
, vol.32
, pp. 62-67
-
-
-
2
-
-
84921717634
-
The association of cytotoxic T-lymphocyte antigen-4 + 49/AG and CT60 polymorphisms with type 1 diabetes and latent autoimmune diabetes in Chinese adults
-
COI: 1:CAS:528:DC%2BC28XhvV2quro%3D, PID: 25185645
-
Jin P, Xiang B, Huang G, Zhou Z (2015) The association of cytotoxic T-lymphocyte antigen-4 + 49/AG and CT60 polymorphisms with type 1 diabetes and latent autoimmune diabetes in Chinese adults. J Endocrinol Invest 38(2):149–154
-
(2015)
J Endocrinol Invest
, vol.38
, Issue.2
, pp. 149-154
-
-
Jin, P.1
Xiang, B.2
Huang, G.3
Zhou, Z.4
-
3
-
-
84927916645
-
Vitamin D and autoimmunity: what happens in autoiimune polyendocrine syndromes?
-
COI: 1:CAS:528:DC%2BC28XhvFSjt70%3D, PID: 25576459
-
Bellastella G, Maiorino MI, Petrizzo M, De Bellis A, Capuano A, Esposito K, Giugliano D (2015) Vitamin D and autoimmunity: what happens in autoiimune polyendocrine syndromes? J Endocrinol Invest 38(6):629–633
-
(2015)
J Endocrinol Invest
, vol.38
, Issue.6
, pp. 629-633
-
-
Bellastella, G.1
Maiorino, M.I.2
Petrizzo, M.3
De Bellis, A.4
Capuano, A.5
Esposito, K.6
Giugliano, D.7
-
4
-
-
84994890744
-
Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxivitamin D in children with type 1 diabetes
-
COI: 1:CAS:528:DC%2BC28Xhtl2kt7%2FK, PID: 27541155
-
Talaat IM, Nasr A, Alsulaimani AA, Alghamdi H, Alswat KA, Almalki DM, Abushouk A, Saleh AM, Alla G (2016) Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxivitamin D in children with type 1 diabetes. J Endocrinol Invest 39(12):1425–1434
-
(2016)
J Endocrinol Invest
, vol.39
, Issue.12
, pp. 1425-1434
-
-
Talaat, I.M.1
Nasr, A.2
Alsulaimani, A.A.3
Alghamdi, H.4
Alswat, K.A.5
Almalki, D.M.6
Abushouk, A.7
Saleh, A.M.8
Alla, G.9
-
5
-
-
84978890727
-
Review: perspectives and clinical implications of bone marrow and circulating stem cell defects in diabetes
-
PID: 27401837
-
Fadini GP, Ciciliot S, Albiero M (2017) Review: perspectives and clinical implications of bone marrow and circulating stem cell defects in diabetes. Stem Cells 35(1):106–116
-
(2017)
Stem Cells
, vol.35
, Issue.1
, pp. 106-116
-
-
Fadini, G.P.1
Ciciliot, S.2
Albiero, M.3
-
6
-
-
84930763863
-
The rise, fall, and resurgence of immunotherapy in type 1 diabetes
-
COI: 1:CAS:528:DC%2BC2cXhtlCisL7F, PID: 25107501
-
Ben Nasr M, D’Addio F, Usuelli V, Tezza S, Abdi R, Fiorina P (2015) The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 98:31–38
-
(2015)
Pharmacol Res
, vol.98
, pp. 31-38
-
-
Ben Nasr, M.1
D’Addio, F.2
Usuelli, V.3
Tezza, S.4
Abdi, R.5
Fiorina, P.6
-
7
-
-
0033933211
-
Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology
-
COI: 1:STN:280:DC%2BD3cvps1entA%3D%3D, PID: 10882147
-
Kemink SAG, Hermus ARMM, Swinkles LMJW, Lutterman JA, Smals AGH (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23(5):295–303
-
(2000)
J Endocrinol Invest
, vol.23
, Issue.5
, pp. 295-303
-
-
Kemink, S.A.G.1
Hermus, A.R.M.M.2
Swinkles, L.M.J.W.3
Lutterman, J.A.4
Smals, A.G.H.5
-
8
-
-
1842328005
-
Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment
-
COI: 1:STN:280:DyaK2s3ltFagsQ%3D%3D, PID: 9096915
-
Astorri E, Fiorina P, Gavaruzzi G, Astorri A, Magnati G (1997) Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment. Cardiology 88(2):152–155
-
(1997)
Cardiology
, vol.88
, Issue.2
, pp. 152-155
-
-
Astorri, E.1
Fiorina, P.2
Gavaruzzi, G.3
Astorri, A.4
Magnati, G.5
-
9
-
-
84940035191
-
Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice
-
COI: 1:CAS:528:DC%2BC28XhvFSju78%3D, PID: 25863666
-
Zhukouskaya VV, Eller-Vainicher C, Shepelkevich AP, Dydyshko Y, Cairoli E, Chiodini I (2015) Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice. J Endocrinol Invest 38(9):941–950
-
(2015)
J Endocrinol Invest
, vol.38
, Issue.9
, pp. 941-950
-
-
Zhukouskaya, V.V.1
Eller-Vainicher, C.2
Shepelkevich, A.P.3
Dydyshko, Y.4
Cairoli, E.5
Chiodini, I.6
-
10
-
-
84863937073
-
Rising incidence and challenges of childhood diabetes. A mini review
-
COI: 1:STN:280:DC%2BC38nhvV2jtg%3D%3D, PID: 22572768
-
Cizza G, Brown RJ, Rother KI (2012) Rising incidence and challenges of childhood diabetes. A mini review. J Endocrinol Invest 35(5):541–546
-
(2012)
J Endocrinol Invest
, vol.35
, Issue.5
, pp. 541-546
-
-
Cizza, G.1
Brown, R.J.2
Rother, K.I.3
-
11
-
-
84883719529
-
Severe hypoglycemic episodes: a persistent threat for children with type 1 diabetes mellitus and their families
-
COI: 1:STN:280:DC%2BC3svnvVKjuw%3D%3D, PID: 23511311
-
Maltoni G, Zucchini S, Scipione M, Rollo A, Balsamo C, Bertolini C, Baronio F, Rondelli R, Pession A (2013) Severe hypoglycemic episodes: a persistent threat for children with type 1 diabetes mellitus and their families. J Endocrinol Invest 36(8):617–621
-
(2013)
J Endocrinol Invest
, vol.36
, Issue.8
, pp. 617-621
-
-
Maltoni, G.1
Zucchini, S.2
Scipione, M.3
Rollo, A.4
Balsamo, C.5
Bertolini, C.6
Baronio, F.7
Rondelli, R.8
Pession, A.9
-
12
-
-
70349673424
-
Immunotherapy for the prevention and treatment of type 1 diabetes
-
COI: 1:CAS:528:DC%2BD1MXhtlehs7jN, PID: 19794002
-
Rewers M, Gottlieb P (2009) Immunotherapy for the prevention and treatment of type 1 diabetes. Diabetes Care 32(10):1769–1782
-
(2009)
Diabetes Care
, vol.32
, Issue.10
, pp. 1769-1782
-
-
Rewers, M.1
Gottlieb, P.2
-
13
-
-
24944520907
-
Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study
-
PID: 16168295
-
Perseghin G, Fiorina P, De Cobelli F, Scifo P, Esposito A, Canu T, Danna M, Gremizzi C, Secchi A, Luzi L, Del Maschio A (2005) Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. J Am Coll Cardiol 46(6):1085–1092
-
(2005)
J Am Coll Cardiol
, vol.46
, Issue.6
, pp. 1085-1092
-
-
Perseghin, G.1
Fiorina, P.2
De Cobelli, F.3
Scifo, P.4
Esposito, A.5
Canu, T.6
Danna, M.7
Gremizzi, C.8
Secchi, A.9
Luzi, L.10
Del Maschio, A.11
-
14
-
-
85017549210
-
Quercetin potentiates transdifferentiation of bone marrow mesenchymal stem cells into the beta cells in vitro
-
PID: 28000178
-
Miladpour B, Rasti M, Owji AA, Mostafavipour Z, Khoshdel Z, Noorafshan A, Zal F (2016) Quercetin potentiates transdifferentiation of bone marrow mesenchymal stem cells into the beta cells in vitro. J Endocrinol Invest. doi:10.1007/s40618-016-0592-8
-
(2016)
J Endocrinol Invest
-
-
Miladpour, B.1
Rasti, M.2
Owji, A.A.3
Mostafavipour, Z.4
Khoshdel, Z.5
Noorafshan, A.6
Zal, F.7
-
15
-
-
0018701862
-
Monoclonal antibodies defining distinctive human T cell surface antigens
-
COI: 1:STN:280:DyaL3c%2FhsVCqsQ%3D%3D, PID: 314668
-
Kung P, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206(4416):347–349
-
(1979)
Science
, vol.206
, Issue.4416
, pp. 347-349
-
-
Kung, P.1
Goldstein, G.2
Reinherz, E.L.3
Schlossman, S.F.4
-
16
-
-
0019851727
-
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody
-
COI: 1:STN:280:DyaL387nslWmsA%3D%3D, PID: 7041358
-
Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Russell PS (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32(6):535–539
-
(1981)
Transplantation
, vol.32
, Issue.6
, pp. 535-539
-
-
Cosimi, A.B.1
Burton, R.C.2
Colvin, R.B.3
Goldstein, G.4
Delmonico, F.L.5
LaQuaglia, M.P.6
Russell, P.S.7
-
17
-
-
0037198420
-
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD38XktVansLY%3D, PID: 12037148
-
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone J (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N engl J Med 346:1692–1698
-
(2002)
N engl J Med
, vol.346
, pp. 1692-1698
-
-
Herold, K.C.1
Hagopian, W.2
Auger, J.A.3
Poumian-Ruiz, E.4
Taylor, L.5
Donaldson, D.6
Gitelman, S.E.7
Harlan, D.M.8
Xu, D.9
Zivin, R.A.10
Bluestone, J.11
-
18
-
-
20544443927
-
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
-
COI: 1:CAS:528:DC%2BD2MXls1Wqu7k%3D, PID: 15972866
-
Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N engl J Med 352(25):2598–2608
-
(2005)
N engl J Med
, vol.352
, Issue.25
, pp. 2598-2608
-
-
Keymeulen, B.1
Vandemeulebroucke, E.2
Ziegler, A.G.3
Mathieu, C.4
Kaufman, L.5
Hale, G.6
Gorus, F.7
Goldman, M.8
Walter, M.9
Candon, S.10
Schandene, L.11
Crenier, L.12
De Block, C.13
Seigneurin, J.M.14
De Pauw, P.15
Pierard, D.16
Weets, I.17
Rebello, P.18
Bird, P.19
Berrie, E.20
Frewin, M.21
Waldmann, H.22
Bach, J.F.23
Pipeleers, D.24
Chatenoud, L.25
more..
-
19
-
-
67649933375
-
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years
-
COI: 1:CAS:528:DC%2BD1MXotl2gu7g%3D, PID: 19443276
-
Herold K, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Group Immune Tolerance Network ITN007AI Study (2009) Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 132 (2): 166–173
-
(2009)
Clin Immunol
, vol.132
, Issue.2
, pp. 166-173
-
-
Herold, K.1
Gitelman, S.2
Greenbaum, C.3
Puck, J.4
Hagopian, W.5
Gottlieb, P.6
Sayre, P.7
Bianchine, P.8
Wong, E.9
Seyfert-Margolis, V.10
Bourcier, K.11
Bluestone, J.A.12
-
20
-
-
80051471700
-
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC3MXpvFWltbs%3D
-
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. The Lancet 378(9790):487–497
-
(2011)
The Lancet
, vol.378
, Issue.9790
, pp. 487-497
-
-
Sherry, N.1
Hagopian, W.2
Ludvigsson, J.3
Jain, S.M.4
Wahlen, J.5
Ferry, R.J.6
Bode, B.7
Aronoff, S.8
Holland, C.9
Carlin, D.10
King, K.L.11
Wilder, R.L.12
Pillemer, S.13
Bonvini, E.14
Johnson, S.15
Stein, K.E.16
Koenig, S.17
Herold, K.C.18
Daifotis, A.G.19
-
21
-
-
84887052291
-
Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders
-
COI: 1:CAS:528:DC%2BC3sXhsleisr7J, PID: 23835333
-
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team (2013) Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766–3774
-
(2013)
Diabetes
, vol.62
, Issue.11
, pp. 3766-3774
-
-
Herold, K.C.1
Gitelman, S.E.2
Ehlers, M.R.3
Gottlieb, P.A.4
Greenbaum, C.J.5
Hagopian, W.6
Boyle, K.D.7
Keyes-Elstein, L.8
Aggarwal, S.9
Phippard, D.10
Sayre, P.H.11
McNamara, J.12
Bluestone, J.A.13
-
22
-
-
84896116224
-
Efficacy and safety of low-dose Otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study
-
COI: 1:CAS:528:DC%2BC2cXktlCgtL8%3D, PID: 24236828
-
Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM (2014) Efficacy and safety of low-dose Otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabetic Med 31 (4):399–402.
-
(2014)
Diabetic Med
, vol.31
, Issue.4
, pp. 399-402
-
-
Ambery, P.1
Donner, T.W.2
Biswas, N.3
Donaldson, J.4
Parkin, J.5
Dayan, C.M.6
-
23
-
-
77956377698
-
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice
-
COI: 1:CAS:528:DC%2BC3cXht12kurfK, PID: 20805386
-
Vergani A, D’Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E, Deng S, Rodig SJ, Ansari JM, Staudacher C, Abdi R, Williams J, Markmann J, Atkinson M, Sayegh MH, Fiorina P (2010) A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 59(9):2253–2264
-
(2010)
Diabetes
, vol.59
, Issue.9
, pp. 2253-2264
-
-
Vergani, A.1
D’Addio, F.2
Jurewicz, M.3
Petrelli, A.4
Watanabe, T.5
Liu, K.6
Law, K.7
Schuetz, C.8
Carvello, M.9
Orsenigo, E.10
Deng, S.11
Rodig, S.J.12
Ansari, J.M.13
Staudacher, C.14
Abdi, R.15
Williams, J.16
Markmann, J.17
Atkinson, M.18
Sayegh, M.H.19
Fiorina, P.20
more..
-
24
-
-
84962673275
-
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 years results of a randomized trial
-
COI: 1:CAS:528:DC%2BC28XlvFCmur4%3D, PID: 27053235
-
Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR (2016) Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 years results of a randomized trial. Diabetologia 59(6):1153–1161
-
(2016)
Diabetologia
, vol.59
, Issue.6
, pp. 1153-1161
-
-
Gitelman, S.E.1
Gottlieb, P.A.2
Felner, E.I.3
Willi, S.M.4
Fisher, L.K.5
Moran, A.6
Gottschalk, M.7
Moore, W.V.8
Pinckney, A.9
Keyes-Elstein, L.10
Harris, K.M.11
Kanaparthi, S.12
Phippard, D.13
Ding, L.14
Bluestone, J.A.15
Ehlers, M.R.16
-
25
-
-
84920413163
-
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes
-
PID: 25500887
-
Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA (2015) Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest 125(1):448–455
-
(2015)
J Clin Invest
, vol.125
, Issue.1
, pp. 448-455
-
-
Haller, M.J.1
Gitelman, S.E.2
Gottlieb, P.A.3
Michels, A.W.4
Rosenthal, S.M.5
Shuster, J.J.6
Zou, B.7
Brusko, T.M.8
Hulme, M.A.9
Wasserfall, C.H.10
Mathews, C.E.11
Atkinson, M.A.12
Schatz, D.A.13
-
26
-
-
58149359257
-
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes
-
COI: 1:CAS:528:DC%2BD1MXhsleisrk%3D, PID: 18689692
-
Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleri I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH (2008) Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57:3013–3024
-
(2008)
Diabetes
, vol.57
, pp. 3013-3024
-
-
Fiorina, P.1
Vergani, A.2
Dada, S.3
Jurewicz, M.4
Wong, M.5
Law, K.6
Wu, E.7
Tian, Z.8
Abdi, R.9
Guleri, I.10
Rodig, S.11
Dunussi-Joannopoulos, K.12
Bluestone, J.13
Sayegh, M.H.14
-
27
-
-
36849027817
-
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
-
COI: 1:CAS:528:DC%2BD2sXhsValsL%2FP, PID: 18060033
-
Hu C, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomichik MJ, Wen L (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117:3857–3867
-
(2007)
J Clin Invest
, vol.117
, pp. 3857-3867
-
-
Hu, C.1
Rodriguez-Pinto, D.2
Du, W.3
Ahuja, A.4
Henegariu, O.5
Wong, F.S.6
Shlomichik, M.J.7
Wen, L.8
-
28
-
-
70449480577
-
Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function
-
COI: 1:CAS:528:DC%2BD1MXhsFSnsbnP, PID: 19940299
-
Pescovitz MD, Grrenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wehrret D, Wilson DM, Lachen JM, Skyler JS (2009) Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N engl J Med 361:2143–2152
-
(2009)
N engl J Med
, vol.361
, pp. 2143-2152
-
-
Pescovitz, M.D.1
Grrenbaum, C.J.2
Krause-Steinrauf, H.3
Becker, D.J.4
Gitelman, S.E.5
Goland, R.6
Gottlieb, P.A.7
Marks, J.B.8
McGee, P.F.9
Moran, A.M.10
Raskin, P.11
Rodriguez, H.12
Schatz, D.A.13
Wehrret, D.14
Wilson, D.M.15
Lachen, J.M.16
Skyler, J.S.17
-
29
-
-
0037198427
-
Effects of insulin in relatives of patients with type 1 diabetes mellitus
-
Diabetes Prevention Trial—Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N engl J Med 346(22):1685–1691
-
(2002)
N engl J Med
, vol.346
, Issue.22
, pp. 1685-1691
-
-
-
30
-
-
18144391496
-
Effects of oral insulin in relatives of patients with type 1 diabetes
-
Diabetes Prevention Trial - Type 1 Diabetes Study Group (2005) Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 28(5):1068–1076
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1068-1076
-
-
-
31
-
-
79960743608
-
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial
-
COI: 1:CAS:528:DC%2BC3MXpt1Ons7c%3D, PID: 21714999
-
Wherrett DK, Bundy B, Becker DJ, Di Meglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes Trial Net GAD Study Group (2011). Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial. Lancet 378(9788):319–27.
-
(2011)
Lancet
, vol.378
, Issue.9788
, pp. 319-327
-
-
Wherrett, D.K.1
Bundy, B.2
Becker, D.J.3
Di Meglio, L.A.4
Gitelman, S.E.5
Goland, R.6
Gottlieb, P.A.7
Greenbaum, C.J.8
Herold, K.C.9
Marks, J.B.10
Monzavi, R.11
Moran, A.12
Orban, T.13
Palmer, J.P.14
Raskin, P.15
Rodriguez, H.16
Schatz, D.17
Wilson, D.M.18
Krischer, J.P.19
Skyler, J.S.20
more..
-
32
-
-
2942703755
-
A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX)
-
Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, manca Bitti ML, Bizzarri C, Pozzilion P (2004). A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 150:719–724
-
(2004)
Eur J Endocrinol
, vol.150
, pp. 719724
-
-
Crinò, A.1
Schiaffini, R.2
Manfrini, S.3
Mesturino, C.4
Visalli, N.5
Beretta Anguissola, G.6
Suraci, C.7
Pitocco, D.8
Spera, S.9
Corbi, S.10
Matteoli, M.C.11
Patera, I.P.12
manca Bitti, M.L.13
Bizzarri, C.14
Pozzilion, P.15
-
33
-
-
77950636402
-
Failure to preserve β-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes
-
COI: 1:CAS:528:DC%2BC3cXlsleqtLo%3D, PID: 20067954
-
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS (2010) Failure to preserve β-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 33(4):826–832
-
(2010)
Diabetes Care
, vol.33
, Issue.4
, pp. 826-832
-
-
Gottlieb, P.A.1
Quinlan, S.2
Krause-Steinrauf, H.3
Greenbaum, C.J.4
Wilson, D.M.5
Rodriguez, H.6
Schatz, D.A.7
Moran, A.M.8
Lachin, J.M.9
Skyler, J.S.10
-
34
-
-
77955653658
-
Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3cXptleit7o%3D, PID: 20440520
-
Sobel DO, Henzke A, Abbassi V (2010) Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 47(3):243–250
-
(2010)
Acta Diabetol
, vol.47
, Issue.3
, pp. 243-250
-
-
Sobel, D.O.1
Henzke, A.2
Abbassi, V.3
-
35
-
-
84878300647
-
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
-
COI: 1:CAS:528:DC%2BC3sXls1Sit7s%3D, PID: 23562090
-
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T. (2013). Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 (9881): 1905–1915.
-
(2013)
Lancet
, vol.381
, Issue.9881
, pp. 1905-1915
-
-
Moran, A.1
Bundy, B.2
Becker, D.J.3
DiMeglio, L.A.4
Gitelman, S.E.5
Goland, R.6
Greenbaum, C.J.7
Herold, K.C.8
Marks, J.B.9
Raskin, P.10
Sanda, S.11
Schatz, D.12
Wherrett, D.K.13
Wilson, D.M.14
Krischer, J.P.15
Skyler, J.S.16
Pickersgill, L.17
de Koning, E.18
Ziegler, A.G.19
Böehm, B.20
Badenhoop, K.21
Schloot, N.22
Bak, J.F.23
Pozzilli, P.24
Mauricio, D.25
Donath, M.Y.26
Castaño, L.27
Wägner, A.28
Lervang, H.H.29
Perrild, H.30
Mandrup-Poulsen, T.31
more..
-
36
-
-
40949104315
-
The future of IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis
-
COI: 1:CAS:528:DC%2BD1cXisl2isbw%3D, PID: 18321234
-
Kalliolias GD, Liossis SN (2008) The future of IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17(3):349–359
-
(2008)
Expert Opin Investig Drugs
, vol.17
, Issue.3
, pp. 349-359
-
-
Kalliolias, G.D.1
Liossis, S.N.2
-
37
-
-
84938085085
-
One week treatment with the IL-1 receptor antagonist Anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus
-
PID: 26073226
-
Van Asseldonk EJ, Van Poppell PC, Ballak DB, Stienstra R, Netea MG, Tack CJ (2015). One week treatment with the IL-1 receptor antagonist Anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol 160 (2):155–162.
-
(2015)
Clin Immunol
, vol.160
, Issue.2
, pp. 155-162
-
-
Van Asseldonk, E.J.1
Van Poppell, P.C.2
Ballak, D.B.3
Stienstra, R.4
Netea, M.G.5
Tack, C.J.6
-
38
-
-
84920059445
-
Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens
-
COI: 1:CAS:528:DC%2BC2MXktVOltQ%3D%3D, PID: 25187361
-
Kleffel S, Vergani A, Tezza S, Ben Nasr M, Niewczas MA, Wong S, Bassi R, D’Addio F, SchattonT, Abdi R, AtkinsonM, Sayegh MH, Wen L, Wasserfall CH, O’Connor KC, Fiorina P (2015) Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens. Diabetes 64(1):158–171
-
(2015)
Diabetes
, vol.64
, Issue.1
, pp. 158-171
-
-
Kleffel, S.1
Vergani, A.2
Tezza, S.3
Ben Nasr, M.4
Niewczas, M.A.5
Wong, S.6
Bassi, R.7
D’Addio, F.8
Schatton, T.9
Abdi, R.10
Atkinson, M.11
Sayegh, M.H.12
Wen, L.13
Wasserfall, C.H.14
O’Connor, K.C.15
Fiorina, P.16
-
39
-
-
34047170241
-
Characterization of donor dendritic cells and enhancement of dendritic cell efflux with cc-chemokine ligand 21. A novel strategy to prolong islet allograft survival
-
COI: 1:CAS:528:DC%2BD2sXktFChtLk%3D, PID: 17287465
-
Fiorina P, Jurewicz M, Tanaka K, Behazin N, Augello A, Vergani A, Von Adrian U, Smith NR, Sayegh MH, Abdi R (2007) Characterization of donor dendritic cells and enhancement of dendritic cell efflux with cc-chemokine ligand 21. A novel strategy to prolong islet allograft survival. Diabetes 56(4):912–920
-
(2007)
Diabetes
, vol.56
, Issue.4
, pp. 912-920
-
-
Fiorina, P.1
Jurewicz, M.2
Tanaka, K.3
Behazin, N.4
Augello, A.5
Vergani, A.6
Von Adrian, U.7
Smith, N.R.8
Sayegh, M.H.9
Abdi, R.10
-
40
-
-
84875427488
-
Regulatory T cells: recommendations to simplify the nomenclature
-
COI: 1:CAS:528:DC%2BC3sXktFygtr8%3D, PID: 23507634
-
Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF (2013) Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14(4):307–308
-
(2013)
Nat Immunol
, vol.14
, Issue.4
, pp. 307-308
-
-
Abbas, A.K.1
Benoist, C.2
Bluestone, J.A.3
Campbell, D.J.4
Ghosh, S.5
Hori, S.6
Jiang, S.7
Kuchroo, V.K.8
Mathis, D.9
Roncarolo, M.G.10
Rudensky, A.11
Sakaguchi, S.12
Shevach, E.M.13
Vignali, D.A.14
Ziegler, S.F.15
-
41
-
-
84869165311
-
Dendritic cell therapy for type 1 diabetes suppression
-
COI: 1:CAS:528:DC%2BC38Xhs1Kms7nP, PID: 23148758
-
Giannoukakis N, Trucco M (2012) Dendritic cell therapy for type 1 diabetes suppression. Immunotherapy 4 (10):1063–1074.
-
(2012)
Immunotherapy
, vol.4
, Issue.10
, pp. 1063-1074
-
-
Giannoukakis, N.1
Trucco, M.2
-
42
-
-
34047170241
-
Characterization of donor dendritic cells and enhancement of dendritic cell efflux with cc-Chemokine ligand 21
-
COI: 1:CAS:528:DC%2BD2sXktFChtLk%3D, PID: 17287465
-
Fiorina P, Jurewicz M, Tanaka K, Behazin N, Augello A, Vergani A, Adrian UV, Smith NR, Sayegh MH, Abdi R (2007) Characterization of donor dendritic cells and enhancement of dendritic cell efflux with cc-Chemokine ligand 21. Diabetes 56(4):912–920
-
(2007)
Diabetes
, vol.56
, Issue.4
, pp. 912-920
-
-
Fiorina, P.1
Jurewicz, M.2
Tanaka, K.3
Behazin, N.4
Augello, A.5
Vergani, A.6
Adrian, U.V.7
Smith, N.R.8
Sayegh, M.H.9
Abdi, R.10
-
43
-
-
84856094049
-
Phase I (Safety) study of 12 autologous tolerogenic dendritic cells in type 1 diabetic patients
-
Giannouakis N, Phillips B, Finegold D, Harnah J, Trucco M (2011) Phase I (Safety) study of 12 autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34:2026–2032
-
(2011)
Diabetes Care
, vol.34
, pp. 2026-2032
-
-
Giannouakis, N.1
Phillips, B.2
Finegold, D.3
Harnah, J.4
Trucco, M.5
-
44
-
-
84954443667
-
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
-
Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q (2015) Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 7(315):1–14
-
(2015)
Sci Transl Med
, vol.7
, Issue.315
, pp. 1-14
-
-
Bluestone, J.A.1
Buckner, J.H.2
Fitch, M.3
Gitelman, S.E.4
Gupta, S.5
Hellerstein, M.K.6
Herold, K.C.7
Lares, A.8
Lee, M.R.9
Li, K.10
Liu, W.11
Long, S.A.12
Masiello, L.M.13
Nguyen, V.14
Putnam, A.L.15
Rieck, M.16
Sayre, P.H.17
Tang, Q.18
-
45
-
-
84877673917
-
Stem cell therapy to cure type 1 diabetes: from hype to hope
-
COI: 1:CAS:528:DC%2BC3sXosFKnsrs%3D, PID: 23572052
-
Chhabra P, Brayman KL (2013) Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cells Transl Med 2(5):328–336.
-
(2013)
Stem Cells Transl Med
, vol.2
, Issue.5
, pp. 328-336
-
-
Chhabra, P.1
Brayman, K.L.2
-
46
-
-
70249122431
-
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes
-
COI: 1:CAS:528:DC%2BD1MXotFWgtbg%3D, PID: 19561093
-
Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183(2):993–1004
-
(2009)
J Immunol
, vol.183
, Issue.2
, pp. 993-1004
-
-
Fiorina, P.1
Jurewicz, M.2
Augello, A.3
Vergani, A.4
Dada, S.5
La Rosa, S.6
Selig, M.7
Godwin, J.8
Law, K.9
Placidi, C.10
Smith, R.N.11
Capella, C.12
Rodig, S.13
Adra, C.N.14
Atkinson, M.15
Sayegh, M.H.16
Abdi, R.17
-
47
-
-
84919461730
-
Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy
-
PID: 24894496
-
D’Addio F, Trevisani A, Ben Nasr M, Bassi R, El Essawy B, Abdi R, Secchi A, Fiorina P (2014) Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy. Acta Diabetol 51(6):897–904
-
(2014)
Acta Diabetol
, vol.51
, Issue.6
, pp. 897-904
-
-
D’Addio, F.1
Trevisani, A.2
Ben Nasr, M.3
Bassi, R.4
El Essawy, B.5
Abdi, R.6
Secchi, A.7
Fiorina, P.8
-
48
-
-
78650071907
-
Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes
-
COI: 1:CAS:528:DC%2BC3MXlsValtw%3D%3D, PID: 20841611
-
Jurewicz M, Sunmi Y, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P, Atkinson M, Sayegh MH, Abdi R (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59(12):3139–3147
-
(2010)
Diabetes
, vol.59
, Issue.12
, pp. 3139-3147
-
-
Jurewicz, M.1
Sunmi, Y.2
Augello, A.3
Godwin, J.G.4
Moore, R.F.5
Azzi, J.6
Fiorina, P.7
Atkinson, M.8
Sayegh, M.H.9
Abdi, R.10
-
49
-
-
83755195365
-
Immunological applications of stem cells in type 1 diabetes
-
COI: 1:CAS:528:DC%2BC38XhsVKgtLk%3D, PID: 21862682
-
Fiorina P, Zavazava N (2011) Immunological applications of stem cells in type 1 diabetes. Endocr Rev 32(6):725–754
-
(2011)
Endocr Rev
, vol.32
, Issue.6
, pp. 725-754
-
-
Fiorina, P.1
Zavazava, N.2
-
50
-
-
84921899603
-
Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells
-
COI: 1:CAS:528:DC%2BC2MXislGhu74%3D, PID: 25204974
-
Carlsson PO, Schwarz E, Korsgren O, Le Blanc K (2015) Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 64(2):587–592
-
(2015)
Diabetes
, vol.64
, Issue.2
, pp. 587-592
-
-
Carlsson, P.O.1
Schwarz, E.2
Korsgren, O.3
Le Blanc, K.4
-
51
-
-
84962092490
-
Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion
-
COI: 1:CAS:528:DC%2BC28XitVGltrnK, PID: 26628416
-
Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J (2016) Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care 39(1):149–157
-
(2016)
Diabetes Care
, vol.39
, Issue.1
, pp. 149-157
-
-
Cai, J.1
Wu, Z.2
Xu, X.3
Liao, L.4
Chen, J.5
Huang, L.6
Wu, W.7
Luo, F.8
Wu, C.9
Pugliese, A.10
Pileggi, A.11
Ricordi, C.12
Tan, J.13
-
52
-
-
34247154341
-
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD2sXktFeitL0%3D, PID: 17426276
-
Voltarelli JC, Couri CE, Starcieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14):1568–1576
-
(2007)
JAMA
, vol.297
, Issue.14
, pp. 1568-1576
-
-
Voltarelli, J.C.1
Couri, C.E.2
Starcieri, A.B.3
Oliveira, M.C.4
Moraes, D.A.5
Pieroni, F.6
Coutinho, M.7
Malmegrim, K.C.8
Foss-Freitas, M.C.9
Simoes, B.P.10
Foss, M.C.11
Squiers, E.12
Burt, R.K.13
-
53
-
-
84906674143
-
Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis
-
PID: 24947362
-
D’Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, Ning G, Snarski E, Fiorina P (2014) Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 63:3041–3046
-
(2014)
Diabetes
, vol.63
, pp. 3041-3046
-
-
D’Addio, F.1
Valderrama Vasquez, A.2
Ben Nasr, M.3
Franek, E.4
Zhu, D.5
Li, L.6
Ning, G.7
Snarski, E.8
Fiorina, P.9
|